Clinical trials: Prostatic Cancer
Prostate Cancer
Effects of a New Diagnostic Test on the Care of Prostate Cancer Patients: The ProMark™ Clinical Utility Study
The objectives of this study are to assess clinical practice variation in prostate cancer diagnosis and treatment among urologists and how ProMark™ affects clinical practice decision-making.
- Trial name
- NCT04550416
- Testing
- ProMark Information and Test Results
- Where
- United States
- Volunteers
- 217 people, healthy volunteers welcome
- Sponsor
- Qure Healthcare, LLC
Prostatic Neoplasms, Castration-Resistant, Prostate Cancer
A COMbined progRamme of Exercise and Dietary ADvice in mEn With Castrate Resistant Prostate Cancer
The proposed study will assess the feasibility of an exercise and dietary intervention in men with castrate resistant prostate cancer with secondary outcomes assessing improvements in physical functioning, fatigue, quality of…
- Trial name
- COMRADE (NCT03017417)
- Testing
- Exercise Intervention, standard of care
- Where
- United Kingdom
- Volunteers
- 31 people
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
Prostate Cancer
Post-operative or Early Salvage XRT and ADT for High Risk PCa
RATIONALE: Conformal radiation therapy uses a 3-dimensional (3-D) image of the tumor to help focus thin beams of radiation directly on the tumor.
- Trial name
- NCT00949962
- Testing
- antiandrogen therapy, leuprolide acetate, 3-dimensional conformal radiation therapy
- Where
- France
- Volunteers
- 87 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Prostate Cancer
Everolimus, Bicalutamide, and Leuprolide Acetate in Treating Patients Undergoing Radiation Therapy For High-Risk Locally Advanced Prostate Cancer
RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Androgens can cause the growth of prostate cancer cells.
- Trial name
- NCT00943956
- Testing
- bicalutamide, everolimus, leuprolide acetate
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Breast Cancer, Prostate Cancer
Eligibility Screening for the NIH Intramural Research Program Clinical Protocols
The purpose of this protocol is to provide patients with adequate informed consent to understand that screening tests with minimal health risk will be performed to evaluate their eligibility for a research study.
- Conditions
- Breast Cancer, Prostate Cancer, Lung Cancer, Sarcoma
- Trial name
- NCT00026754
- Where
- United States
- Volunteers
- 19,522 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Triptorelin, Flutamide, and External-Beam Radiation Therapy or External-Beam Radiation Therapy Alone in Treating Patients With Stage II or Stage III Prostate Cancer
RATIONALE: Androgens can cause the growth of prostate cancer cells. Drugs, such as triptorelin and flutamide, may stop the adrenal glands from making androgens. Radiation therapy uses high-energy x-rays to kill tumor cells.
- Trial name
- NCT00104741
- Testing
- flutamide, triptorelin, radiation therapy
- Where
- 31 sites in France
- Volunteers
- 378 people
- Sponsor
- UNICANCER
Prostatic Neoplasms, Digital Rectal Examination
Learning Curve of Digital Rectal Examination for Prostate Cancer Among Internship
The investigators conduct this prospective study to investigate the learning curve of digital rectal examination (DRE) for prostate cancer among internship.
- Conditions
- Prostatic Neoplasms, Digital Rectal Examination, Benign Prostatic Hyperplasia
- Trial name
- NCT03479359
- Testing
- Routine review of DRE results by attending doctors
- Where
- China
- Volunteers
- 700 people
- Sponsor
- Changhai Hospital
Prostate Cancer
Implant and External Radiation for Prostate Cancer With or Without Hormonal Therapy: A Prospective Randomized Trial
Determine the role of androgen deprivation therapy in high risk patients receiving 45 Gy of pelvic radiotherapy plus a Pd-103 boost and the impact of the duration of ADT in hormonally-manipulated patients.
- Trial name
- NCT00243646
- Testing
- External beam radiation, Lupron, Casodex
- Where
- 3 sites in United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Schiffler Cancer Center
Stage II Prostate Adenocarcinoma, Stage III Prostate Adenocarcinoma
Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery
This randomized phase II trial studies how well androgen receptor antagonist ARN-509 works with or without abiraterone acetate, gonadotropin-releasing hormone agonist, and prednisone in treating patients with high-risk prostate…
- Trial name
- NCT02949284
- Testing
- Abiraterone Acetate, Androgen Receptor Antagonist ARN-509, Gonadotropin-releasing Hormone Analog
- Where
- 2 sites in United States
- Volunteers
- 90 people
- Sponsor
- Rutgers, The State University of New Jersey
Prostate Cancer
Molecular Studies and Clinical Correlations in Human Prostatic Disease
The Genitourinary Oncology/Urology Services at Memorial Sloan-Kettering Cancer Center (MSKCC) participates in research for the control, treatment, and cure of cancer.
- Trial name
- NCT00578240
- Where
- United States
- Volunteers
- 5,290 people
- Sponsor
- Memorial Sloan Kettering Cancer Center